The process of developing new small-molecule drugs is divided into two phases, namely, drug discovery and drug development. Drug discovery is defined as the process through which potential new drug molecules are identified. It is a multi-stage process, involving a wide range of scientific disciplines, including biology, chemistry and pharmacology.
The key processes involved in drug discovery include: target identification and validation, hit generation and selection, leads identification and lead optimization.
Rise in the demand for small-molecule drugs; dominance of small molecules in the market; increasing number of contract organizations for R&D; and the use of small molecules in treatment of chronic diseases are the factors driving the growth of small-molecule drug discovery market.
High drug development cost and strict regulations by government authorities for the approval of small molecules are hindering the growth of global small-molecule drug discovery market.
The global small-molecule drug discovery market has been segmented on the bases of (a) therapeutic area (oncology, central nervous system, cardiovascular, respiratory, metabolic, gastrointestinal, orthopedics, anti-infective, dermatology, immunological and others), (b) process phase (target ID/validation, hit generation and selection, lead identification and lead optimization) (c) and by geography (North America, Europe, Asia-pacific, Latin America and Middle East & Africa).
The report provides detailed overview of the small-molecule drug discovery market, along with in-depth analysis and company profiles of major players. It provides a clear picture of the competitive landscape that exists currently in this market.
Key players, who enjoy major market share of the small-molecule drug market and have more such products in pipeline, are mentioned.
Key Deliverables in the Study
Market analysis for the global small-molecule drug discovery market, with region-specific assessments and competition analysis.
Market definition, along with the identification of key drivers, restraints, opportunities and challenges.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section, with company profiles of key players and the analyses of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the global small-molecule drug discovery market.
Insights into the market in the regions that have the highest potential for growth, identification of the still-untapped markets.
Related Topics: Global Biobanks Market for Drug Discovery & Regenerative Medicine Growth, Trends and Forecasts (2016 - 2021)
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER'S FIVE FORCES ANALYSIS
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
5.3 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
5.3.1 MARKET DRIVERS
184.108.40.206 RISE IN THE DEMAND FOR SMALL-MOLECULE DRUGS
220.127.116.11 DOMINANCE OF SMALL MOLECULES IN THE MARKET
18.104.22.168 INCREASING NUMBER OF CONTRACT ORGANIZATIONS FOR R&D
22.214.171.124 SMALL MOLECULES IN TREATMENT OF CHRONIC DISEASES
126.96.36.199 HIGH R&D EXPENDITURE IN SMALL-MOLECULE DRUGS
5.3.2 MARKET RESTRAINTS
188.8.131.52 HIGH DRUG DEVELOPMENT COST
184.108.40.206 STRICT REGULATIONS
5.3.4 KEY CHALLENGES
6. MARKET SEGMENTATION
6.1 SEGMENTATION BY THERAPEUTIC AREA
6.1.2 CENTRAL NERVOUS SYSTEM
6.2 SEGMENTATION BY PROCESS PHASE
6.2.1 TARGET ID/VALIDATION
6.2.2 HIT GENERATION AND SELECTION
6.2.3 LEAD IDENTIFICATION
6.2.4 LEAD OPTIMIZATION
6.3 SEGMENTATION BY GEOGRAPHY
6.3.1 NORTH AMERICA
6.3.4 LATIN AMERICA
6.3.5 MIDDLE EAST & AFRICA
7. COMPETITIVE LANDSCAPE
7.1 MERGERS AND ACQUISITION ANALYSIS
7.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
7.3 NEW PRODUCT LAUNCHES
8. KEY PLAYERS
9. FUTURE OUTLOOK OF THE MARKET
- Abbvie Inc
- Albany Molecular Research Inc
- Allergan Plc
- Amgen Inc
- Astellas Pharma Inc
- Astrazeneca Plc
- Atellas Pharma Inc
- Bayer Ag
- Biocon Ltd
- Boehringer Ingelheim Gmbh
- Bristol-Myers Squibb Company
- Charles River Laboratories International Inc
- Eli Lilly and Company
- Evotec Ag
- F Hoffmann-La Roche Ag
- Gilead Sciences Inc
- Glaxosmithkline Plc
- Johnson & Johnson
- Laboratory Corporation of America Holdings
- Merck & Co Inc
- Merck Kgaa
- Novartis Ag
- Novo Nordisk
- Pfizer Inc
- Teva Pharmaceuticals